Samer Nasr, M.D. Mount Lebanon Hospital..  Lone atrial fibrillation:  Younger than 60 years old.  No clinical or echo evidence of cardiopulmonary.

Slides:



Advertisements
Similar presentations
Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
Advertisements

New Atrial Fibrillation/Flutter Pathway and GRASP Tool
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.
RATE CONTROL V/S RHYTHM CONTROL IN AF
Atrial fibrillation.
ATRIAL FIBRILLATION Linda A. Snyder, MSN, CRNP. Definition: A common arrhythmia characterized by chaotic, rapid, discontinuous atrial depolarizations.
Peking University Dayi Hu Sept 16, IHF,Beijing, 2005 Atrial Fibrillation in China.
Atrial Fibrillation Update 2012 Dr C Seifer Section of Cardiology St Boniface Hospital.
Phillip H. Lam, M.D. Chief Medical Resident Medstar Georgetown University Hospital.
Atrial fibrillation wavelets propagating in different directions disorganised atrial depolarisation without effective atrial contraction f waves
Atrial fibrillation Daniel Gutenberger M.D. Chief Medical Director American General, Milwaukee.
Arrhythmias: The Good, the Bad and the Ugly
1 Clinical Overview of Atrial Fibrillation Edward L.C. Pritchett, M.D. Consulting Professor of Medicine Divisions of Cardiology and Clinical Pharmacology.
Atrial Fibrillation Steve McGlynn
NILOFAR RAHMAN, MD AMIT KUMAR, MD. DEFINITION  A SVT with uncoordinated atrial activation with constant deterioration of atrial mechanical function 
Cardioversion of Atrial Fibrillation Clinical Issues Christopher Granger, MD Director, Cardiac Care Unit Duke University Medical Center December 2007.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
Atrial Fibrillation. Statistics 1.5% of people over 65 have AF 1.5% of people over 65 have AF 5x increased risk of stroke 5x increased risk of stroke.
Clinical Title Date Jaret Tyler, MD Clinical Cardiac Electrophysiologist Assistant Professor of Medicine Ohio State’s Heart and Vascular Center Atrial.
Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary’s University of London.
Amr Kamal, M.D Alexandria Main University Hospital Alexandria- Egypt ECRA 2010.
Cardioversion Curriculum. Learning Objectives At the conclusion of this activity, the learner will be able to: Identify appropriate.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Yasmine Darwazeh FY1 – General Surgery
Dr Avinash Haridas Pillai
New Agents Heather Kertland, PharmD.
Amiodarone Use in Cardiac Surgical Resuscitation
Atrial Fibrillation Dr Nidhi Bhargava 8/10/13.
Atrial Fibrillation Rate or rhythm control? Who should be anticoagulated? Other treatment strategies.
Muhammad S Ajmal MBBS Aravind Herle MD FACC. Atrial fibrillation (AF) A supraventricular tachyarrhythmia characterized by uncoordinated atrial activation.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Randomized, double-blind, multicenter, controlled trial.
Prof. C. Moro, Madrid Non antiarrhythmic drugs for AF.
Atrial Fibrillation Current Management Strategies.
Atrial Fibrillation What is New in the 2006 ACC/AHA/ESC Guidelines HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation. May 2007.
Atrial Fibrillation DR. DAYANAND NAIK, MD, FACC; CLINICAL ASSOCIATE PROFESSOR, NEW YORK MEDICAL COLLEGE.
Atrial Fibrillation t Alfred Vulpian- ‘Fremissement fibrillaire’ 1876 Carl Nothnagel- ‘Delerium Cordis’
Randomized, double blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients.
Overview of the AFFIRM Study
EP Show – December 2002 AFFIRM The EP Show: AFFIRM Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital The Care Group.
Atrial Fibrillation Ablation: Who and Why ?
Grace Thacker Xavier University of Louisiana LSUHC – Internal Medicine
Treatment of Atrial Fibrillation M Samson – PGY-2 Riverside Campus July 17, 2015 Academic Day.
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
1 AF: Issues with Anticoagulation AFL: Anticoagulation like AF When undergoing procedures with risk for bleeding: May DC warfarin for up to one week without.
1 Tedisamil for Conversion of Atrial Fibrillation Thomas A. Marciniak, M.D. Division of Cardiovascular and Renal Products U.S. Food & Drug Administration.
1 Risk/Benefit Assessment Jeremy N. Ruskin, M.D. Director, Cardiac Arrhythmia Services Massachusetts General Hospital.
Amiodarone versus Sotalol for Atrial Fibrillation N Engl J Med 2005;352: Bramah N. Singh, M.D., D.Sc., Steven N. Singh, M.D., Domenic J. Reda, Ph.D.,
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
A. Marc Gillinov, MD For the Cardiothoracic Surgical Trials Network (CTSN) ACC April 2016 RATE VERSUS RHYTHM CONTROL FOR ATRIAL FIBRILLATION AFTER CARDIAC.
Increased mortality among patients taking digoxin—analysis from the AFFIRM study or Lack of evidence of increased mortality among patients with atrial.
Palpitations & Atrial Fibrillation Dr Mehul B Dhinoja, Consultant Cardiologist & Electrophysiologist BMI The London Independent Hospital.
Atrial Fibrillation: An old age problem PCCS Village Hotel 18 th May 2011.
Atrial Fibrillation Jay H. Lee, MD Denver Health Medical Center Wednesday 2 July 2008.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA/ESC 2006 Guidelines for the Management of.
Journal of the American College of Cardiology Vol. 61, No. 4, 2013 Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation.
Women and Cardiovascular Disease
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Zoll Firm Lecture Series
AF Basics for Office Visits Patient Education
Κολπικη μαρμαρυγη σε ασθενεις με αποφρακτικη υπνικη απνοια
Atrial fibrillation (AF) and flutter
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Fibrillazione atriale
ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.
What oral antiplatelet therapy would you choose?
NICE 2014 Check pulse in patients presenting with:
Presentation transcript:

Samer Nasr, M.D. Mount Lebanon Hospital.

 Lone atrial fibrillation:  Younger than 60 years old.  No clinical or echo evidence of cardiopulmonary disease.  Favorable prognosis.  Thromboembolism usually not an issue.  Substrate related atrial fibrillation.  ETOH Hyperthyroidism HTN  Surgery Metabolic disorders Cardiomyopathy  MI Obesity Sleep apnea  Pericarditis Valvular disease  Myocarditis Heart failure  PE CAD

AF: Treatment Options Rhythm normalization - AA drugs IaIcIII New AAd - Cardioversion - Non AA drugs - AF Ablation Ratenormalization - AV node blockers BB - DIG CA - … - AV node ablation Strokeprevention -Pharmacologic AC ++ Aspirin New AT drugs -Nonpharmacologic Removal/isolation LA appendage Anti – coagulation INR: 2-3

 Rate of progression to permanent atrial fibrillation.  Prognosis

First Episode Paroxysmal (recurrent) Permanent No recurrence

the Canadian Registry of Atrial Fibrillation Am Heart J 2005;149: patients

UK Registry. BMC Cardiovascular Disorders 2005, 5: patients

Olmsted County Circulation. 2007;115: Year Follow-Up

=> the risk of progression to permanent atrial fibrillation is around 20% in young patients => Up to 30% of patients will not recur their AF after the first episode

UK Registry BMC Cardiovascular Disorders 2005, 5: patients 5 y F-U * Relative risk estimated by Cox regression model, including age, sex, smoking, heart failure, ischaemic heart disease, hypertension, cerebrovascular disease and diabetes.

Olmsted County Circulation. 2007;115: Long-term observed survival in lone AF 30-Year Follow-Up

=> Patients with lone atrial fibrillation have a normal life expectancy. => Comorbidities significantly modulate AF prognosis and complications: hypertension, diabetes, heart failure, and advancing age …

Long term efficacy of Anti-arrhythmic drugs

Roy D, et al. New Engl J Med. 2000;342:913–920. CTAF Study: % of Patients Remaining Free of Recurrence of AF Days of Follow-up Patients Without Recurrence (%) Amiodarone (n = 201) Sotalol (n = 101) Propafenone (n = 101)

Adverse Effects of Oral Amiodarone Zimetbaum P. N Engl J Med 2007;356:

 Out patient management of PAF can be performed using:  Pill-in- the-pocket.  Amiodarone.  Dronaderone.

1. A beta-blocker or NDHP Ca-blocker. 2. Half an hour later ; if symptoms persist:  Propafenone: ▪ 600 mg if > 70kg ▪ 450mg if <70 KG  Flecanide: ▪ 300 mg if >70 kg. ▪ 200 mg if < 70 kg.  Only once in 24 hour period.

 2 68 patients presenting to ER with AF. given Flecanide or Propafenone. ▪ 58 had treatment failure or side effects; excluded ▪ Out-of-Hospital self administration of Flecanide or Propafenone studied in remaining 210. ▪ 79 percent had episodes of arrhythmias  92 % treated 36±93 minutes after sx onset  Treatment succesful in 94% of episodes.  Alboni P, et al. NEJM, 2004;351:23.

Alboni P, et al. N Engl J Med. 2004;351: episodes per month

 Treat the first episode inpatient with IC antiarrhythmics.  Make sure QT interval stays unchanged with therapy.  Perform exercise stress test on therapy and document QRS interval stability prior to initiating pill-in-the-pocket technique.

 Outpatient therapy of Lone AF can be performed safely and effectively if thorough patient selection with appropriate work up is performed.  QOL is The main goal of outpatient therapy.

Dosages and precautions

Electrophysiological Action of Amiodarone Zimetbaum P. N Engl J Med 2007;356:

 Baseline screening studies should include tests of liver, thyroid, and pulmonary function as well as chest radiography.  It is reasonable to initiate amiodarone therapy in the outpatient setting.

 A slightly reduced loading dose (e.g., 600 mg per day in one dose or divided doses for 3 to 4 weeks) is reasonable.  The patient should undergo electrocardiography weekly or should be discharged with a loop recorder to monitor heart rhythm, heart rate, and duration of the QT interval.  If conversion has not occurred by the end of the loading period, electrical cardioversion should be performed, followed by a reduction in the dose of amiodarone to 200 mg daily.

Hohnloser. N Engl J Med 2009;360: ATHENA study dronedarone A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation / atrial flutter

Dronedarone reduces Cardiovascular Death Hohnloser. N Engl J Med 2009;360: ATHENA study

Dronedarone reduces the incidence of cardiovascular hospitalization or death Hohnloser. N Engl J Med 2009;360: ATHENA study

 Meta-analysis on Dronaderone vs Amiodarone: From ANDROMEDA to. DIONYSOS.  Dronaderone less effective than amiodarone for atrial fibrillation with an odds ratio of 0.5. ▪ Less Side Effects. ▪ Less efficacy.  Dronaderone trades efficacy for safety.  Piccini et al, J. Am Coll Cardiol. 2009: 54:

 Lone atrial fibrillation: a benign disease.  Strict rules should apply to outpatient therapy.  Careful initial screening for underlying heart disease is imperative.  Frequent reevaluation of the substrate is a must to ensure that organic heart disease has not occurred with time.